National Comprehensive Cancer Network

About NCCN

Updated NCCN Guidelines Adaptations Assist Middle East and North Africa Clinicians Treating Patients with Breast, Hepatobiliary, and Non-Small Cell Lung Cancers and Lymphomas

By Jorge Bacigalupo, Global Business Development Specialist, NCCN

The National Comprehensive Cancer Network® (NCCN®) recently posted the updated Middle East & North Africa (MENA) Editions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for following disease types:

  • Breast Cancer, Version 2.2016
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2017
  • Hairy Cell Leukemia, Version 2.2017
  • Hepatobiliary Cancers, Version 2.2016
  • Hodgkin Lymphoma, Version 1.2017
  • Non-Small Cell Lung Cancer, Version 4.2017
  • Primary Cutaneous B-Cell Lymphomas, Version 2.2017
  • T-Cell Lymphomas, Version 2.2017

NCCN continues to work closely with the MENA Coordinating Office for NCCN Collaborations, situated at the King Abdulaziz Medical City in Riyadh, Saudi Arabia; these adaptations are part of a larger endeavor between the two organizations to adapt the NCCN Guidelines® for several disease types.

NCCN regularly collaborates to create and distribute foreign editions, regional adaptations, and consensus statements of the NCCN Guidelines, which are NCCN Guidelines derivatives that allow for consideration of metabolic differences in populations, local accessibility, and regulatory status of health care technologies used in cancer care in the specified country or region. For additional information on NCCN Global Programs, visit NCCN.org/global.

If you would like to learn more about adaptations of the NCCN Guidelines, please contact Jorge Bacigalupo, Bacigalupo@nccn.org.